Gregory Weinhoff Sells 73,196 Shares of Centessa Pharmaceuticals (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) insider Gregory Weinhoff sold 73,196 shares of the stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $26.33, for a total transaction of $1,927,250.68. Following the sale, the insider directly owned 65,925 shares of the company’s stock, valued at approximately $1,735,805.25. The trade was a 52.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Centessa Pharmaceuticals Stock Down 3.3%

Shares of Centessa Pharmaceuticals stock opened at $26.33 on Friday. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36. The company has a market cap of $3.85 billion, a P/E ratio of -14.39 and a beta of 1.55. The firm’s 50 day moving average price is $24.69 and its 200-day moving average price is $24.29. Centessa Pharmaceuticals PLC Sponsored ADR has a 52-week low of $9.60 and a 52-week high of $30.58.

Analysts Set New Price Targets

CNTA has been the topic of a number of recent analyst reports. Chardan Capital reaffirmed a “buy” rating and set a $30.00 price target on shares of Centessa Pharmaceuticals in a research report on Friday, January 2nd. Oppenheimer raised their price objective on Centessa Pharmaceuticals from $40.00 to $62.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 10th. Truist Financial upped their target price on Centessa Pharmaceuticals from $33.00 to $38.00 and gave the company a “buy” rating in a research report on Thursday, January 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 21st. Finally, Wolfe Research started coverage on Centessa Pharmaceuticals in a report on Tuesday, February 24th. They issued an “outperform” rating and a $40.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Centessa Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $39.80.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Campbell & CO Investment Adviser LLC purchased a new position in shares of Centessa Pharmaceuticals during the 2nd quarter valued at about $218,000. American Century Companies Inc. lifted its holdings in shares of Centessa Pharmaceuticals by 3.5% in the 2nd quarter. American Century Companies Inc. now owns 1,130,708 shares of the company’s stock valued at $14,858,000 after buying an additional 37,954 shares during the period. Eagle Health Investments LP purchased a new stake in shares of Centessa Pharmaceuticals in the third quarter worth about $2,500,000. Federated Hermes Inc. purchased a new stake in shares of Centessa Pharmaceuticals in the third quarter worth about $42,429,000. Finally, Royce & Associates LP acquired a new stake in Centessa Pharmaceuticals during the third quarter worth about $5,999,000. 82.01% of the stock is owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.